کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5912638 | 1161442 | 2015 | 27 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Î9-tetrahydrocannabinol acting through CB1 receptors
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
CFAPBSAEAMOGSativexTMEVFAAHPPAREAEcomplete Freund’s adjuvant - adjuvant دوست کاملanandamide - آناندامیدexperimental autoimmune encephalomyelitis - آنسفالومیلیت خودایمنی تجربیTherapeutic effects - اثرات درمانیFatty acid amide hydrolase - اسید آمینه هیدرولاز اسید چربCNS - دستگاه عصبی مرکزیBlood–brain barrier - سد خونی مغزیBBB - سد خونی مغزیcentral nervous system - سیستم عصبی مرکزیCSF - مایع مغزی نخاعیCerebrospinal fluid - مایع مغزی نخاعیPhosphate-buffered saline - محلول نمک فسفات با خاصیت بافریMultiple sclerosis - مولتیپل اسکلروزیس(ام اس)Theiler's murine encephalomyelitis virus - ویروس encephalomyelitis موشی تیلرCUPID - کوپیدmyelin oligodendrocyte glycoprotein - گلیکوپروتئین الیگودندروسیت میلینCB1 receptors - گیرنده CB1CB1 receptor - گیرنده CB1CB2 receptor - گیرنده CB2peroxisome proliferator-activated receptor - گیرنده فعال فعال پروکسیومcannabinoid type-1 receptor - گیرنده نوع 1 کانابینوئیدCannabinoid type-2 receptor - گیرنده نوع 2 کانابینوئید
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
ژنتیک
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Î9-tetrahydrocannabinol acting through CB1 receptors The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Î9-tetrahydrocannabinol acting through CB1 receptors](/preview/png/5912638.png)
چکیده انگلیسی
Sativex®, an equimolecular combination of Î9-tetrahydrocannabinol-botanical drug substance (Î9-THC-BDS) and cannabidiol-botanical drug substance (CBD-BDS), is a licensed medicine that may be prescribed for alleviating specific symptoms of multiple sclerosis (MS) such as spasticity and pain. However, further evidence suggest that it could be also active as disease-modifying therapy given the immunomodulatory, anti-inflammatory and cytoprotective properties of their two major components. In this study, we investigated this potential in the experimental autoimmune encephalitis (EAE) model of MS in mice. We compared the effect of a Sativex-like combination of Î9-THC-BDS (10 mg/kg) and CBD-BDS (10 mg/kg) with Î9-THC-BDS (20 mg/kg) or CBD-BDS (20 mg/kg) administered separately by intraperitoneal administration to EAE mice. Treatments were initiated at the time that symptoms appear and continued up to the first relapse of the disease. The results show that the treatment with a Sativex-like combination significantly improved the neurological deficits typical of EAE mice, in parallel with a reduction in the number and extent of cell aggregates present in the spinal cord which derived from cell infiltration to the CNS. These effects were completely reproduced by the treatment with Î9-THC-BDS alone, but not by CBD-BDS alone which only delayed the onset of the disease without improving disease progression and reducing the cell infiltrates in the spinal cord. Next, we investigated the potential targets involved in the effects of Î9-THC-BDS by selectively blocking CB1 or PPAR-γ receptors, and we found a complete reversion of neurological benefits and the reduction in cell aggregates only with rimonabant, a selective CB1 receptor antagonist. Collectively, our data support the therapeutic potential of Sativex as a phytocannabinoid formulation capable of attenuating EAE progression, and that the active compound was Î9-THC-BDS acting through CB1 receptors.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Multiple Sclerosis and Related Disorders - Volume 4, Issue 6, November 2015, Pages 505-511
Journal: Multiple Sclerosis and Related Disorders - Volume 4, Issue 6, November 2015, Pages 505-511
نویسندگان
Miguel Moreno-Martet, Ana Feliú, Francisco Espejo-Porras, Miriam Mecha, Francisco J Carrillo-Salinas, Javier Fernández-Ruiz, Carmen Guaza, Eva de Lago,